CD2 and CD3 receptor-mediated tolerance - Constraints on T cell activation

被引:8
作者
Punch, JD
Lin, J
Bluestone, J
Bromberg, JS
机构
[1] Univ Michigan, Dept Surg, Div Transplantat, Ann Arbor, MI 48104 USA
[2] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48104 USA
[3] Univ Michigan, Sch Med, Multipurpose Arthrit Ctr, Ann Arbor, MI 48104 USA
[4] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA
[5] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
关键词
D O I
10.1097/00007890-199903150-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Antigen specific allograft tolerance is induced in mice by anti-CDS plus anti-CD3 epsilon monoclonal antibody (mAb) treatment. Because anti-CD2 mAb inhibits several aspects of anti-CD3 epsilon driven T cell activation, we investigated what components of T cell activation are required or may be dispensed with for tolerance induction. Anti-CD3 epsilon-mediated T cell activation depends on Fc gamma R interactions. Methods. To assess the role of Fc gamma R-mediated T cell activation in tolerance induction, Fc gamma R binding IgG or non-binding IgG(3) anti-CD3 epsilon mAbs were examined. Results. These mAbs, administered in conjunction with anti-CD2, were equally effective in inducing tolerance, Moreover, in vivo administration of a blocking mAb directed against the Fc gamma R, or the use of allograft recipients deficient in Fc gamma R, had no effect on tolerance induction. Blocking IL-2 using mAb directed against IL-2 or IL-2R also did not prevent the induction of tolerance. These results suggest that complete T cell activation was not required for tolerance induction, However, substitution of a partially activating mAb, directed against the T cell receptor (TCR) beta subunit for anti-CD3 epsilon, failed to synergize with anti-CD2 mAb to induce tolerance. The anti-TCR beta mAb and anti-CD3 epsilon mAb were found to differentially down modulate expression of TCR/CD3 complex subunits, In particular, anti-CD3 epsilon caused transient down modulation of the TCR beta receptor subunit and the TCR zeta signaling module, and this pattern was enhanced and prolonged by anti-CD2. Anti-TCR beta caused persistent TCR zeta modulation but no TCR beta modulation, and anti-CD2 did not influence this pattern. Conclusions. These results suggest that, although full T cell activation is not required for the induction of tolerance by anti-CD2 plus anti-CD3 epsilon mAb, a signal transduction pathway that is associated with TCR beta and TCR zeta expression, and, specifically, is perturbed by mAb binding of the CD3 epsilon epitope, is critical.
引用
收藏
页码:741 / 748
页数:8
相关论文
共 43 条
[1]  
ALEGRE ML, 1995, J IMMUNOL, V155, P1544
[2]   ANTIBODY 12-15 CROSS-REACTS WITH MOUSE FC-GAMMA RECEPTORS AND CD2 - STUDY OF THYMUS EXPRESSION, GENETIC-POLYMORPHISM AND BIOSYNTHESIS OF THE CD2 PROTEIN [J].
ALTEVOGT, P ;
KOHL, U ;
VONHOEGEN, P ;
LANG, E ;
SCHIRRMACHER, V .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (02) :341-346
[3]   ANTI-CD2 MONOCLONAL-ANTIBODIES ALTER CELL-MEDIATED-IMMUNITY INVIVO [J].
BROMBERG, JS ;
CHAVIN, KD ;
ALTEVOGT, P ;
KYEWSKI, BA ;
GUCKEL, B ;
NAJI, A ;
BARKER, CF .
TRANSPLANTATION, 1991, 51 (01) :219-225
[4]  
CEUPPENS JL, 1985, J IMMUNOL, V135, P388
[5]   PROLONGATION OF ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE BY ANTI-CD2 MONOCLONAL-ANTIBODIES [J].
CHAVIN, KD ;
LAU, HT ;
BROMBERG, JS .
TRANSPLANTATION, 1992, 54 (02) :286-291
[6]  
CHAVIN KD, 1993, J IMMUNOL, V151, P7249
[7]   COMBINATION ANTI-CD2 AND ANTI-CD3 MONOCLONAL-ANTIBODIES INDUCE TOLERANCE WHILE ALTERING INTERLEUKIN-2, INTERLEUKIN-4, TUMOR-NECROSIS-FACTOR, AND TRANSFORMING GROWTH-FACTOR-BETA PRODUCTION [J].
CHAVIN, KD ;
QIN, LH ;
LIN, JX ;
WOODWARD, JE ;
BALIGA, P ;
BROMBERG, JS .
ANNALS OF SURGERY, 1993, 218 (04) :492-503
[8]   ANTI-CD2 AND ANTI-CD3 MONOCLONAL-ANTIBODIES SYNERGIZE TO PROLONG ALLOGRAFT SURVIVAL WITH DECREASED SIDE-EFFECTS [J].
CHAVIN, KD ;
QIN, LH ;
LIN, JX ;
KAPLAN, AJ ;
BROMBERG, JS .
TRANSPLANTATION, 1993, 55 (04) :901-908
[9]  
CHAVIN KD, 1994, J IMMUNOL, V152, P372
[10]   CYTOKINES AND PERIPHERAL TOLERANCE TO ALLOANTIGEN [J].
DALLMAN, MJ ;
WOOD, KJ ;
HAMANO, K ;
BUSHELL, AR ;
MORRIS, PJ ;
WOOD, MJA ;
CHARLTON, HM .
IMMUNOLOGICAL REVIEWS, 1993, 133 :5-18